The next wave

India's next pharma leap is being built from the ground up, through a new generation of bulk drug parks. While some are near completion, many are still in early stages but carry strategic importance. These hubs are key to cut API import dependence, secure supply chains, and position India as a globally competitive manufacturing powerhouse

- 

Maha Integrated Life Sciences City Limited (MiLeS City), Maharashtra

One of the key announcements during the Pulse Maharashtra Summit held over March 27-28, 2026 was the unveiling of the state's bulk drug park, to be built by Ramky Infrastructure, under a PPP model with Maharashtra Industrial Development Corporation (MIDC). With substantial initial anchor investments from Pharmax (committed INR 470 crore) and Savvycare (INR 50 crore), the bulk drug park seems off to a good start.

As per a BSE filing of March 13, 2026, MIDC has appointed Maha Integrated Life Sciences City Limited (MILES City), a wholly owned subsidiary of Ramky Infrastructure as a 'developer for the development, operation, maintenance and management of the upcoming high-tech pharmaceutical park in Dighi Port Industrial Area Mangaon and Roha Taluk, Raighad District in the state of Maharashtra on PPP Basis'.

This project has been awarded for a period of 95 years concession including construction period of five years. The project includes development of an industrial park over an area of 1000 hectares in Raigad District of Maharashtra primarily consisting of an Industrial Zone, Commercial Zone, Common Amenities, Utilities, Open spaces and Roads.

As per the filing, the Life Sciences City 'aims to act as a one stop holistic solution to the Life Sciences and Pharma Sector in providing them with all the requisite sustainable Infrastructure for establishing their units.' The total project cost is estimated at around INR 3,000 crores and the company would be able to earn revenue by way of Land Lease Premium, Development Charges, Maintenance income for the Services and Operation income from the Utilities.